We are proud of this recognition and of investing in France to produce, create jobs, and contribute to French excellence for more than a century, with international reach in the healthcare sector.

We are announcing three strategic projects:

✅ The relocation of Colchicine production to France, in the Bourgogne–Franche-Comté region, a medication of major therapeutic interest for patients, which must remain accessible and manufactured in France. 🏭
With a €2.5M investment and a complete industrial transfer to France, we are choosing to strengthen health sovereignty and control the entire value chain to ensure safe, sustainable, and responsible access to treatment for patients. 🎯
The first boxes produced in France, for French patients, are expected in 2026.

✅ The consolidation of global Meteospasmyl production, with an investment of over €15M at our historic site in Dammarie-lès-Lys, in the Île-de-France region, along with the creation of 40 qualified industrial jobs by 2026.
The first boxes were released last month for France and the rest of the world, representing more than €50M in exported production.

✅ Over the next two years, €30M will be invested in production, innovation, decarbonization, and relocation projects in France.

Our key priorities:
✔ Ensuring access to medicines for French patients
✔ Maintaining the economic sustainability of production in France amid increasing international competition
✔ Supporting employment and French know-how
✔ Contributing positively to France’s health and industrial sovereignty, as well as its trade balance

🙏 Thank you to all our national and local elected officials, the Government, and the Élysée for their support sometimes spanning decades and for their commitment and mobilization. This demonstrates that together, in a win–win partnership, we can strengthen health sovereignty in France, just as Mayoly has done with confidence and lasting optimism for 116 years.

No comments yet, be the first to comment.

Leave a Reply